BetterLife Announces Closing of Private Placement

Diamond Therapeutics completes Phase I clinical study of low-dose psilocybin in...

Psychedelic Bulletin #126: Journey’s Mescaline Patent Pledge; Therapeutic Alliance Doesn’t Predict...

COMP360 psilocybin therapy shows potential in open-label study in type II...

Psychedelics Weekly – Genetic Memory, “The Psychedelic Renaissance,” and Harm Reduction...

Webinar: Psychedelic Integration and Depth Relational Process

Abuse Potential: Considerations for Rescheduling MDMA and Psychedelics

PT376 – Ketamine and Psychedelic-Assisted Therapy as Employee Benefits

Psychedelic Bulletin #125: New Data Boosts Spravato’s Case; Bipartisan Breakthrough Therapies...

Psychedelic Research Bulletin: November 2022

Load more